# The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

> **NCT04585750** · PHASE1,PHASE2 · RECRUITING · sponsor: **PMV Pharmaceuticals, Inc** · enrollment: 300 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Advanced Malignant Neoplasm
- Metastatic Cancer
- Metastatic Solid Tumor
- Lung Cancer
- Ovarian Cancer
- Endometrial Cancer
- Prostate Cancer
- Colorectal Cancer
- Breast Cancer
- Other Cancer
- Locally Advanced
- Head and Neck Cancer
- Gall Bladder Cancer
- Small Cell Lung Cancer
- Small Cell Lung Cancer ( SCLC )
- Small Cell Lung Carcinoma
- NSCLC
- NSCLC (Non-small Cell Lung Cancer)
- SCLC
- Non-Small Cell Lung Carcinoma
- Triple Negative Breast Cancer
- TNBC
- HER2+ Breast Cancer
- Non-Small Cell Lung Cancer
- ER/PR Positive Breast Cancer
- HER2- Breast Cancer
- HER2-positive Breast Cancer
- HER2-negative Breast Cancer
- ER/PR(+), Her2(-) Breast Cancer

## Interventions

- **DRUG:** rezatapopt
- **DRUG:** pembrolizumab

## Key facts

- **NCT ID:** NCT04585750
- **Lead sponsor:** PMV Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-10-29
- **Primary completion:** 2026-08-15
- **Final completion:** 2027-12-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04585750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04585750, "The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT04585750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*